Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In Vitro Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A.

Antimicrobial agents and chemotherapy - 1 Nov 2018

Asante-Appiah Ernest, Liu Rong, Curry Stephanie, McMonagle Patricia, Agrawal Sony, Carr Donna, Rokosz Laura, Lahser Frederick, Bystol Karin, Chase Robert, Black Stuart, Ferrari Eric, Ingravallo Paul, Tong Ling, Yu Wensheng, Kozlowski Joseph

Abstract excerpt

Inhibition of NS5A has emerged as an attractive strategy to intervene in hepatitis C virus (HCV) replication. Ruzasvir (formerly MK-8408) was developed as a novel NS5A inhibitor to improve upon the potency and barrier to resistance of early compounds. Ruzasvir inhibited HCV RNA replication with 50% effective concentrations (EC50s) of 1 to 4 pM in Huh7 or Huh7.5 cells bearing replicons for HCV genotype 1 (GT1) to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amides
Share to Cyclopropanes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heterocyclic Compounds, 4 or More Rings

Share to Protease Inhibitors

Share to Pyrrolidines

Share to Quinoxalines

Share to Replicon

Share to Uridine

Source

Open in PubMed Open full text

Identifiers

PMID: 30150466
DOI: 10.1128/AAC.01280-18
PMCID: PMC6201069

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In Vitro Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A.PMID 30150466Read ↗

In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.Semantic proximity Read ↗

In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir.Semantic proximity Read ↗

Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885.Semantic proximity Read ↗

Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4.Semantic proximity Read ↗

HCV Replicon Systems: Workhorses of Drug Discovery and Resistance.Semantic proximity Read ↗

Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons.Semantic proximity Read ↗

<i>In Vitro</i> and <i>In Vivo</i> Antiviral Activity and Resistance Profile of Ombitasvir, an Inhibitor of Hepatitis C Virus NS5ASemantic proximity Read ↗

Preclinical characterization of GSK2336805, a novel inhibitor of hepatitis C virus replication that selects for resistance in NS5A.Semantic proximity Read ↗

Identification of hepatitis C virus NS5A inhibitors.Semantic proximity Read ↗

Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.Semantic proximity Read ↗

Hepatitis C virus NS5A inhibitors and drug resistance mutations.Semantic proximity Read ↗

Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.